Table 6 Comparison of means for biochemical parameters by triple therapy combinations—DPP4I study, Anuradhapura 2017
Therapy | Investigation | |||||
|---|---|---|---|---|---|---|
No. of patients | HbA1C (%) | Pancreatic amylase (U/L) | Serum lipase (U/L) | AST (U/L) | ALT (U/L) | |
OOH group [mean (SD)] | ||||||
Metformin-glibenclamide-pioglitazone | 01 | 7.8 | 41 | 46 | 14 | 12 |
Metformin-glimepiride-pioglitazone | 01 | 7.9 | 80 | 41 | 55 | 43 |
Metformin SR-tolbutamide-pioglitazone | 01 | 6.8 | 80 | 45 | 27 | 16 |
DPP4I group [mean (SD)] | ||||||
Sitagliptin-metformin-gliclazide | 20 | 9.4 (1.6) | 43.4 (17.8) | 58.1 (28.2) | 27 (11.4) | 30.7 (21.4) |
Sitagliptin-metformin SR-gliclazide | 06 | 9.1 (1.9) | 36 (15.5) | 55.8 (22.3) | 28.7 (8.3) | 29 (12.2) |
Sitagliptin-metformin-gliclazide MR | 05 | 8.6 (2) | 65.6 (35.8) | 96.6 (55.4) | 38.2 (26.6) | 50.8 (40.8) |
Sitagliptin-metformin SR-gliclazide MR | 02 | 8.4 (3.3) | 44 (8.5) | 67 (35.4) | 20.5 (12) | 32.5 (30.4) |
Sitagliptin-metformin-glimepiride | 10 | 8.1 (2) | 35.7 (7.2) | 41.5 (13.9) | 35.9 (27.7) | 25.6 (10.6) |
Sitagliptin-metformin SR-glimepiride | 09 | 7.6 (1.1) | 57.8 (49.4) | 109.8 (157.7) | 24.9 (10.3) | 29.6 (18.9) |
Sitagliptin-metformin-tolbutamide | 02 | 8.1 (2.8) | 42 (11.3) | 52 (4.2) | 24.5 (3.5) | 25 (7.1) |
Vildagliptin-metformin SR-gliclazide | 01 | 8.5 | 36 | 84 | 28 | 34 |
Vildagliptin-metformin SR-gliclazide MR | 01 | 10.1 | 43 | 57 | 13 | 10 |